In today’s recent session, 0.48 million shares of the Carisma Therapeutics Inc (NASDAQ:CARM) have been traded, and its beta is 1.52. Most recently the company’s share price was $1.14, and it changed around $0.02 or 2.23% from the last close, which brings the market valuation of the company to $47.56M. CARM at last check was trading at a discount to its 52-week high of $9.77, offering almost -757.02% off that amount. The share price’s 52-week low was $0.99, which indicates that the recent value has risen by an impressive 13.16% since then. We note from Carisma Therapeutics Inc’s average daily trading volume that its 3-month average coming to 185.01K.
Carisma Therapeutics Inc (NASDAQ:CARM) trade information
Instantly CARM has been showing a green trend so far today with a performance of 2.23% on intraday trading today. The performance over the last five days has remained in the green territory. The company’s shares are currently down -60.92% year-to-date, but still up 11.17% over the last five days. On the other hand, Carisma Therapeutics Inc (NASDAQ:CARM) is -9.13% down in the 30-day period.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 81.0% from its current value. Analyst projections state that CARM is forecast to be at a low of $6 and a high of $6.
Carisma Therapeutics Inc (CARM) estimates and forecasts
Carisma Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -60.52 percent over the past six months and at a 33.59% annual growth rate that is well above the industry average of 13.20%. The year-over-year growth rate is expected to be 4.00%, up from the previous year.
Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 3.92M in revenue for the current quarter. 4 analysts expect Carisma Therapeutics Inc to make 4.3M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 3.56M and 3.83M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 10.10%. Forecasts for the next quarter put sales growth at 12.40%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 24.98%.
CARM Dividends
Carisma Therapeutics Inc’s next quarterly earnings report is expected to be released in July.
